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reprogrammable multifunctional manipulator designed to 
move materials, parts, tools, or specialized devices through 
variable programmed motions for the performance of a 
variety of tasks defined by The Robotics Institute of America. 
Dependent on the degree of automation and autonomy 
different classes can be recognized. Examples where robotic 
systems are used in brachytherapy are e.g. in prostate and 
bladder implantations. 
Several commercial and non-commercial systems exist to 
plan and place needles into the prostate. These systems can 
be automated for radioactive seed delivery and HDR 
treatments. Clinical study show robotic implantations to be 
feasible, although still manual corrections are done. 
In bladder brachytherapy a laparoscopic robotic system is 
available for catheter placement without the need to open 
the bladder (cystotomy). As with the traditional way of 
implanting, the catheters can be placed parallel and 
equidistantly. The major advantage is reduction of treatment 
morbidity with this technique, although also misplacements 
have been observed preventing adequate brachytherapy. 
Development of new technologies, such as robotic-aided 
brachytherapy implantations is welcomed to increase the 
precision and reproducibility of treatments and reduce 
morbidity. On the other side it should be appreciated that 
also for these techniques a learning curve exist. Clinical 
results in comparison to the traditional techniques should be 
awaited and carefully discussed before widespread 
adaptation of these new techniques. 
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Interventional radiotherapy (brachytherapy) was the first 
medical application in the treatment of cancer after 
discovering radium. User experience was growing over the 
time and useful rules of meaningful applicaton were 
developed. For many decades this experience based rules 
regulated the indication as well the performance of 
brachytherapy applications. After introducing milestone 
developments in the technical performance (stepping source 
technology and modern treatment planning software 
packages) as well in target definition modalities 
(multiparametric imaging, real-time imaging) and in quality 
assurance issues (medical & physical QA) biological planning 
and intensity modulation potential become available. 
Furthermore, interdisciplinary networking and education in 
the field lead to a higher level of cure rates with low toxicity 
and better Quality of Life of the patients. Economical 
comparison with other methods proved the necessity of 
involving interventional radiotherapy in to modern function 
preservative interdisciplinary treatments.  
Head & Neck cancer represents a special need for 
interdisciplinary cooperation because:  
1. Most of the recurrences following modern external beam 
radiotherapy (with or without complementary systemic 
treatment) are in-field recurrences. This indicates the need 
for higher local dose and interventional radiotherapy offers 
the highest possible dose in a small volume accompanied by 
very low radiation dose on surrounding normal tissues or 
organs at risk.  
2. Aggressive surgery cause functional or cosmetic demages 
on the head & neck. The combination of surgery and 
perioperative interventional radiotherapy results in higher 
rates of function preservation or in better cosmetic results.  
3. Modern multiparametric imaging techniques including 
hypoxia imaging has the potential to guide necessary very 
high dose areas to the right but very small volumes within the 
target.  
Regarding healthcare economy issues: preliminary analyses of 
healthcare professionals stated the advantage of involving 
interventional radiotherapy in to the treatment of head & 
neck cancers.  
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Vaginal cancer is a rare disease, accounting for only 2-3% of 
all gynaecological cancers. The majority (85%) of the tumours 
are squamous cell carcinomas and associated with a previous 
HPV infection.  
The FIGO classification is used for clinical staging and is an 
important prognostic factor. Approximately 25% of patients 
present with FIGO stage I, limited to the vaginal wall with a 
5-year survival rate of approximately 80%, compared to 20% 
for FIGO stage IV tumours that invade other pelvic organs or 
extend beyond the true pelvis (10-15% of patients). Other 
known prognostic factors are site, size and histologic 
subtype.  
The treatment of vaginal cancer may include surgery in 
limited stage I disease, in the upper third of the vagina. 
However, surgery is often extensive especially if tumors 
extend to the lower two thirds of the vagina and it is often 
difficult to achieve negative margins in tumors larger than 2-
3 cm. Because of these difficulties, radiotherapy is generally 
recommended as the standard treatment for all vaginal 
cancers irrespectively of the stage.  
In general, radiotherapy is very similar to that for cervical 
cancer and includes a combination of 45-50 Gy external beam 
radiotherapy (EBRT) with concomitant weekly cisplatinum 
followed by brachytherapy boost to a total dose of 70 Gy to 
80 Gy. With regard to the brachytherapy technique small 
residual tumors (≤5mm thick) can be treated with 
intracavitary technique alone while combined intracavitary 
and interstitial technique should be considered for larger 
tumours.  
Published data on the results of radiotherapy are mainly 
based on small retrospective studies and can be categorised 
in two groups. The first group includes studies where patients 
mainly were treated with 2-dimensional (x-ray based) 
radiotherapy. The second small group includes studies where 
patients have been treated using image guided (CT or MRI) 
adaptive treatment planning. Any direct comparison between 
the two groups of studies is difficult because of the 
retrospective nature of the data, limited number of patients 
and short follow-up. However, it seems that image guided 
brachytherapy is associated an increased local control rate 
from 75% (44-87%) for the radiograph based studies to 85% 
(75-94%) for the studies using an image guided approach, 
together with a decrease in moderate to severe treatment 
related morbidity. In 2005 the GEC-ESTRO GYN group 
successfully introduced an image guided adaptive target 
concept for brachytherapy in locally advanced cervical 
cancer. This concept takes the initial tumour extent at time 
of diagnosis as well as tumour regression during EBRT into 
account. Several studies have shown a therapeutic benefit 
with improvements in local control and reductions in 
moderate to severe morbidity using this concept.  
Based on these results, a task group within GEC ESTRO GYN 
was formed with the aim to introduce image guided adaptive 
target concept in the treatment of vaginal cancer. This 
initiative started in the beginning of 2014 comparing the 
different target concepts from each of the 5 involved 
centres. In a next step each centre contoured 5 different 
cases with their own target concept in mind. During this work 
many similarities were found in the target concepts and 
between the contours of each centre. Therefore the group 
proceeded to investigate the differences and similarities in 
dose and treatment planning. In this project each centre 
performed treatment planning for the 5 contoured cases 
using both their own target contours and on a set of contours 
that were provided.  
Importantly, radiotherapy for vaginal cancer is based on a 
combination of clinical findings as well as imaging. Especially 
for the clinical findings the precise documentation can be 
challenging. In order to increase the uniform reporting a 
clinical drawing for this documentation has been developed. 
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This practical tool is now at the stage that it will be 
evaluated clinically in each centre. By now several centres 
have experience with image guided adaptive brachytherapy 
in limited numbers of patients with vaginal cancer. To gain 
more knowledge from this already existing experience a 
retrospective database has been established with inclusion of 
approximately 90 patients that have been treated with CT or 
MRI guided brachytherapy. Although different target concepts 
have been used, this cohort will allow for analysis of disease 
control, prognostic factors and descriptive analysis of the 
radiotherapy related parameters in a more contemporary 
series. A future goal will be establishment of a prospective 
multicentre database with inclusion of patients treated with 
a common target concept.  
During this presentation existing results for radiotherapy in 
vaginal cancer will be reviewed, followed by an overview of 
the work that has been performed to introduce image guided 
adaptive brachytherapy in primary vaginal cancer within the 
GEC ESTRO GYN group. 
 
Symposium: Quantitative imaging to individualise 
radiotherapy  
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In this presentation the possibilities for image quantification 
for tissue characterization will be discussed that go beyond 
quantification of Hounsfield Units for CT or SUV for PET 
imaging. Standardization aspects of advanced imaging 
techniques are important for reliable and robust 
quantification. Besides the image acquisition, an equally 
important part is validation of the used image analysis 
techniques. Especially for textural feature calculations (e.g. 
radiomics) this is not a trivial task and may require some 
more detailed guidelines for acquisition, segmentation, 
analysis and reporting of results. The entire pipeline from 
image acquisition to analysis should be designed to allow 
interchangeable and robust results between e.g. institutes, 
software packages and imaging equipment. This presentation 
will illustrate the possibilities of advanced image 
quantification, concepts and techniques with clinical 
examples: Radiomics of tumours are currently investigated to 
predict local control, metastasis patterns or survival of 
patients, whereas advanced image quantification of normal 
tissues may allow better prediction of patients prone to 
toxicity. 
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Solid tumors may be heterogeneous with respect to 
radiosensitivity, and a homogeneous tumor dose is thus not 
always optimal. Thus, medical images of radiobiological 
relevance may be used to guide focal irradiation of tumors. 
Tumor control probability (TCP) modeling may be useful for 
optimizing dose painting treatment plans and for estimating 
the effect of such therapeutic strategies.  
Both magnetic resonance imaging and positron emission 
tomography may provide voxel-by-voxel maps potentially 
reflecting tumor aggressiveness and radioresistance. The talk 
will elaborate on the biological relevance of theses imaging 
approaches and their pros and cons in terms of radiotherapy 
planning. Then, from the voxelwise mapping of tumor 
radiosensitivity, proposed frameworks for the tumor control 
probability modelling will be presented. Both data-driven and 
model-driven approaches are discussed. Furthermore, the 
potential use of TCP modelling in dose painting will be 
elaborated. Also, the concept of ‘LET’ painting in particle 
therapy will be highlighted. 
In concluding, the current and future role of image based 
TCP modelling will be discussed, seen together with both 
advances in biologic imaging and in radiotherapy delivery and 
guidance techniques. 
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In this era, image-guided radiotherapy provides the 
technology to modulate dose based on the variation in 
radiation sensitivity within cancer of the prostate. This raises 
the question what to irradiate and to which dose. Here, 
functional imaging techniques play an essential role. Multi-
parametric (mp) MRI, consisting of T2-weighted, diffusion-
weighted and dynamic contrast-enhanced MRI is a key 
element in the detection of prostate cancer, and is 
increasingly used for delineation of tumors inside the 
prostate gland. Validation with histopathology however shows 
that tumor detection and particularly tumor delineation is 
challenging. Prostate cancer is often multifocal and small 
lesions (<0.5cm3) are often missed. Tumor sub-volumes with 
low cell and microvessel density that resemble healthy tissue 
are also difficult to find with mp-MRI.The most aggressive 
parts of the tumors, containing high cell and microvessel 
density and a higher Gleason score, are more likely to be 
detected. The heterogeneity in the histopathology of 
prostate cancer together with the limitations of mpMRI in 
detecting small satellites has implications for dose 
prescriptions in radiotherapy. We therefore evaluated the 
potential impact of dose differentiation on the tumor control 
probability (TCP) in prostate radiotherapy using 
histopathological properties of prostate tumors. We defined 
GTV and CTV based on tumor volumes on H&E stained slices 
from prostatectomy specimen of 25 patients. Each patients’ 
TCP was simulated taking into account differences in the cell 
numbers (N0) and Gleason Scores (GS). We further evaluated 
the assumption that these tumors all have the same 
radiosensitivity, or that radiosensitivity decreases with 
increasing Gleason grade. Our results demonstrate feasible 
dose differentiations between GTV and CTV based on the 
heterogeneity in the histopathology of prostate tumors and 
the impact on the TCP of the patient population. We will 
further discuss the different GTV-CTV dose differentiations 
considering heterogeneity only in the number of tumor cells 
or also in the radiosensitivity, based on Gleason grade. 
Further studies in carefully designed clinical trials are needed 
to determine the effect of heterogeneous radiosensitivity on 
the response of individual patients to different regimes of 
radiotherapy. 
 
Proffered Papers: Physics 5: Intra-fraction motion 
management I  
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Purpose or Objective: Intrafraction motion is a challenge for 
accurate delivery of stereotactic body radiation therapy 
(SBRT) in the liver. Real-time treatment adaptation (gating, 
